News & Updates

Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.

A study in Singapore provides further evidence regarding the benefits of poststroke rehabilitation in improving function, reducing disability, and discharging patients. In addition, the results show that body mass index (BMI) in any category does not predict the ability to attain functional independence following inpatient rehabilitation.

Disruption of the delta wave activity while sleeping may be used to pinpoint individuals who are at heightened risk for cardiovascular disease (CVD) and CVD mortality, according to a study.

Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.